SMMT250117P20000
- 3.90
- 0.000.00%
Summit Therapeutics Newsroom
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $44
IBRX Soars 47% on Initial Trials For Cell Therapy Product
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $45 Price Target
Buy Rating Affirmed for Summit Therapeutics Amid Promising Clinical Trials and Regulatory Progress
Citi Downgrades Summit Therapeutics(SMMT.US) to Hold Rating, Raises Target Price to $23
Summit Therapeutics Downgraded to Neutral From Buy at Citi
Summit Therapeutics Analyst Ratings
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $40
Stifel Nicolaus Sticks to Its Buy Rating for Summit Therapeutics (SMMT)
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $45
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $19
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $25
Summit Therapeutics Analyst Ratings